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SmokingSystemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease, characterized by a wide
array of symptoms and organ involvements, leading to varying disease courses and outcome, and ranging
from mild to severe types. In patients with SLE, the incidence and risk of malignancy development is
increased, and mostly non-Hodgkin's lymphoma (NHL), cervical cancer, as well as bronchial carcinomas
occur. Besides others, the common genetic predisposition, chronic antigen stimulus, disproportional immune
responses, as well as the chronic administration of immunosuppressive medications can contribute to the
development of malignancies in lupus.
In this review we present the molecular pathology, as well as the epidemiological and clinical aspects of
malignancies in patients with SLE.
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1.1. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a heterogeneous systemic
autoimmune disease, which encompasses mild to moderate forms, and
also severe, progressive variants. Through the disease course severalNorway. Tel.: +47 22 851155;
l rights reserved.organs and organ-systems can be affected, amongst others the cardio-
vascular, musculoskeletal, excretory, respiratory and nervous systems
[1]. Due to themodernmanagement and increasing novel therapeutical
regimes, the prognosis of the disease is better; the survival in lupus has
increased [2]. In consequence of increasing life expectancy in SLE,
chronic organ damages and late complications, such as malignancy,
have become key determinants of both morbidity and mortality [3].
There is a clear change in the major causes of death in SLE, namely the
previous, directly lupus-related mortality is reduced, while the
frequency of chronic complications, such as cardio-vascular, infectious
and malignancy-associated mortality seems to be increasing in lupus
patients [2,3]. The expanding occurrence of malignancies can be
Table 1
Statistics on malignancy occurrence in systemic lupus erythematosus.
Tarr T et al. [17] Bernatsky et al. [18]
SLE (n) 860 9547
Malignancies (n) 37 431
Prevalence of malignancy (%) 4.3 4.5
SIR 0.89 1.15
Mortality (n) 164 1255
Mortality ratio (%) 19 13.1
Mortality due to malignancies (n) 18 114
Mortality due to malignancies ⁎%(%) 2% (11%) 1.2% (9.1%)
SMR 1.64 0.8
Age at the time of the diagnosis of
malignancy (years)
46.7 43
SLE duration (years) 13.4 10
Abbreviations: SIR: standardized incidence ratio; SLE: systemic lupus erythematosus;
SMR: standardized mortality ratio; ⁎%(%): malignancy-related mortality of all SLE
patients (malignancy-related mortality of deceased SLE patients).
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development of neoplasms. This phenomenon is reinforced by the
following notions: generally, in autoimmune diseases malignancies
occur with high frequencies; in neoplastic disorders, autoimmune
diseases can develop, as part of the paraneoplastic syndrome; also,
immunosuppressive treatment in autoimmune diseases increases the
development of malignancies [4–8].
Another link between lupus and malignant diseases can be
served by antiphospholipid antibodies (aPL), frequently present in
SLE and cancer as well. A recent publication indicates that aPL can be
a risk factor both for thrombotic processes and cancer development
[9].
A pooled analysis of reported autoimmune conditions and the risk
of non-Hodgkin's lymphoma (NHL) based on 29,423 participants
indicated several important correlations: Sjögren's syndrome (SS)
was associated with a 6.5-fold increased risk of acquiring NHL, there
was a 1000-fold increased risk of parotid gland marginal zone (MZ)
lymphoma development and also diffuse large B-cell lymphoma
(DLBCL) showed association with SS. SLE was associated with a 2.7-
fold increased risk of DLBCL and MZ lymphomas [10]. Taken these
ﬁndings together we assume that in SLE patients with secondary SS
the probability of NHL development may be increased even further,
therefore this clinical condition poses danger and this special subset of
lupus patients requires thorough follow-up and regular screening for
malignancies.
1.2. Common pathogenic pathways in SLE and malignancies
From the etiopathogenic point of view, lupus and various
malignancies have common pathogenic background; the genetic
predisposition, mutual provoking factors (UV light), viral infection
(Epstein–Barr virus), also lifestyle-related risk factors (smoking,
obesity). Besides, hormonal factors may represent a link between
autoimmunity and malignancy, including insulin-like growth factor
(IGF), prolactin, estrogen and growth hormone (GH) [11–13].
The long-term, in many instances aggressive immunosuppressive
treatment in lupus is evidently related to the development ofmalignant
transformations and manifest tumors. Besides these common extrinsic
etiological factors, the intrinsic errors of the immune system contribute
to the development of both disease entities [11]. In many systemic
autoimmune diseases, where disproportional humoral autoimmune
responses are pivotal in the pathogenesis (e.g. SLE and SS), exaggerated
B-cell processes exist, resembling B-cell malignancies [14,15]. Both
conditions are characterized by cell-cycle regulation abnormalities,
which affect lymphocyte survival, proliferation and differentiation, as
well. In parallel, programmed cell death is affected, and the longevity of
B-cells is apparent [14,16]. In these processes various cytokines and
soluble mediators, such as IL-6, IL-10 and B-cell activating factor (BAFF/
BLyS) have been shown to play a major role [14,17]. Due to chronic
antigenic stimulation, B cells contribute to the enhanced levels of
circulating BAFF, and also APRIL. The aberrant up-regulation of these
cytokines may initiate a vicious cycle, in which enhanced levels of BAFF
and proliferation-inducing ligand (APRIL) reinforce the systemic
activation of the humoral immune system [18]. Very similar pathogenic
machinery has been introduced in B-cell malignancies too [19], which
presumes the common pathogenic background behind lupus and
malignant transformations. Recent data indicate the importance of
CD8+ cytotoxic T lymphocytes (CTL) in limiting the expansion of
autoreactive B cells. The CTL population is down regulated in lupus, but
mechanisms critical in CTL expansion may differ in SLE from those
observed in other conditions, e.g. tumors and infections [20].
1.3. SLE and malignancies: the clinical picture
We have previously assessed cancer-related morbidity and mortal-
ity, the type of malignancies in lupus patients, and analyzed associationwith immune-suppressive therapy, disease duration, and age based on
860 SLE patients between 1970 and 2004 [21]. A total of 37 patients
presented with cancer, reﬂecting 4.3% cancer-associated morbidity.
Patients were 47 (20–73) years old at the onset of malignancy, which
appeared 13 (1–45) years later than SLE. Cancer prevalence was the
highest in the ﬁrst 5–10 years of lupus. We found breast cancer was
the most common malignancy followed by gastrointestinal tumors,
cervix cancer and hematologic malignancies, bronchial cancer,
followed by bladder, skin, and ovarian cancer. Standardized inci-
dence ratio was the highest for non-Hodgkin's lymphoma and cervix
cancer. Although 76% of patients with cancer received immune-
suppressive therapy besides corticosteroids, no direct correlation
could be conﬁrmed between therapy and malignancy. In this study,
the cancer-associated mortality was 11%, which peaked during the
last 4 years of the study period [21].
In the multi-center study, conducted by Bernatsky et al., the
incidence of cancer in 9547 SLE patients was assessed, compared with
that in the general population (Table 1).Within the average follow-up
of 8 years, 431 cancers occurred. The data conﬁrmed an increased risk
of cancer among patients with SLE. For all cancers combined,
hematologic malignancies, non-Hodgkin's lymphoma, was the lead-
ing cause of death. The data also suggested an increased risk of lung
cancer and hepatobiliary cancer [22] (Table 2).
2. Various malignancies in lupus patients
2.1. Non-Hodgkin's lymphoma and SLE
As previously described, the incidence of NHL in SLE appears to be
3–4× higher, than in the average population (Table 2). Clinically, the
identiﬁcation of NHL in patients with lupus is difﬁcult, since both
diseases share similar characteristic features (lymphadenopathy/
lymphadenomegaly, fever, weight-loss, hepato-splenomegaly, cyto-
penia, positive anti-nuclear antibody/ANA), therefore the correct
differential diagnosis requires thorough investigations and regular
checkup in SLE. Generally, in SLE mainly aggressive type NHL occurs
(diffuse large B cell lymphoma), opposed to SS, where indolent
lymphomas are present (marginal, mantle-cell MALT lymphoma)
[14,23]. As we have discussed previously, the pathogenic background
behind the more frequent presence of NHL in SLE can be due to the
chronic, persistent antigen-stimulus, chronic inﬂammation, uncon-
trolled B-cell proliferation, defected apoptosis, and the increased risk
of oncogene translocation. Common environmental and genetic
factors further contribute to lymphomagenesis in lupus. Concerning
genetic predisposition, one possible explanation for the higher
frequency of NHL in SLE is that major histocompatibility complex
(MHC)-associated genes predispose to both disorders [24]. Moreover,
Table 2
Standardized incidence ratio (SIR) of various malignancies in patients with lupus.
Type of malignancy SIR Tarr [17] SIR Bernatsky [18]











Urinary bladder 0.54 1.23
Hepatobiliary 0.67 2.60
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aberrant B-1 cell proliferation present risk of NHL development [25].
Immunomodulating/immunosuppressive treatment, commonly
used in SLE can also contribute to the development of lymphomagen-
esis, either by directly causing mutagenesis, or by weakening the
“immune surveillance”, which can lead to uncontrolled, disproportional
B cell proliferation. On the other hand, there are also lupus patientswith
NHL, who have not received immunosuppressive treatment previously,
where also the incidence of NHL reaches the highest rate in the 1st year
of SLE, therefore it is highly unlikely that the cumulative dose of
immunosuppressive drugs is in the background.
Finally, since the clinical appearance of NHL and SLE is similar, and
it is sometimes difﬁcult to distinguish the two disease entities in
the initial phases, these raise the possibility that SLE might be a
paraneoplastic syndrome and appears on the grounds of the lymphoid
malignancy.
These ﬁndings suggest that the intricate interplay of all the
aforementioned factors might lead to the development of NHL in SLE
patients.
2.2. Hodgkin's lymphoma and SLE
Hodgkin's lymphoma (HL) is the lymphoid malignancy of the
immune system that is characterized by thepresence of Reed–Sternberg
(RS) cell. Generally, symptoms include the painless enlargement of
lymph nodes, splenomegaly and hepatomegaly. Other symptoms
include fever, weight loss, fatigue, or night sweats. A multi-site cohort
of 9547 SLE subjects was assessed and HL cases were registered. The 5
HL patients within the population showed bimodal incidence curve (2
patients were under 35 years of age, 3 between 56–67 years at the
onset of HL), similarly to the average occurrence of HL. One patient
died during the investigation. The standardized incidence ratio (SIR)
was 2.4, while the pooled analysis combining this data with other
large cohort studies yielded a SIR for HL in SLE, suggesting that risk in
SLE is increased not only for NHL, but also for other malignancies
arising from B-lymphocytes, including HL [26]. Since RS cells are
usually derived from B-lymphocytes, the common pathogenic role of
chronic antigenic stimulation and disproportional B-cell activation
(EBV) in both HL and lupus may explain the increased occurrence of
HL in patients with SLE.
2.3. Lung cancer in SLE patients
The large, multi-site international cohort study of over 9500 SLE
patients from 23 centers was conducted and histology subtype for 30
lung cancer cases was registered. Most (75%) of these 30 cases were
female, with a median age of 61 years. The most common histological
type reported was adenocarcinoma, followed by small cell carcinoma,
and squamous cell carcinoma. One–one case of large cell carcinoma andcarcinoid tumor also occurred.Most (71%) of the lung cancer caseswere
smokers; only the minority (20%) had been previously exposed to
immunosuppressive agents. The histological distribution of the lung
cancers in SLE was similar to the general population, except for the
higher proportion of more uncommon tumors (bronchoalveolar and
carcinoid) [27].
Amongst others, the higher incidence of lung cancer and SLE could
be due to the common genetic background (4p15.1–15.3 and 6p21).
Moreover, pulmonary ﬁbrosis is increased in lupus patients, which
poses an 8–14× relative risk for subsequent lung cancer development.
In 9% of patients with SLE, pneumonitis–ﬁbrosis, as well as
bronchiolitis obliterans organizing pneumonia (BOOP) occur [28].
These clinical features are characterized by chronic inﬂammation and
extensive DNA damage, which can lead to subsequent malignant
transformations in SLE patients.
2.4. Cervical carcinoma and SLE
Recent ﬁndings suggested that womenwith SLE have an increased
risk of cervical dysplasia and atypia on Pap testing compared with the
general female population [29,30]. In the paper of Bernatsky et al.,
data were pooled from SLE cohorts from three centres, altogether
1015 lupus women were included. The median age of the subjects at
time of diagnosis of SLE was 32 years, at the time of this study, the
median age of the subjects was 42 years, and the median duration of
SLE was 9 years. History of sexually transmitted diseases (STDs) and
use of oral contraceptives (OCs) were positively associated with
reports of cervical dysplasia in adjusted analyses. Abnormal Pap test
was found in 134 patients (13.3%). 41.3% of the cohort had been
exposed to immunosuppressives at any time since their SLE diagnosis.
The unadjusted odds ratios (OR) for the effect of immunosuppressive
exposure on abnormal Pap test results occurring after diagnosis of SLE
were 1.2. The OR for the effect of immunosuppressive exposure on
abnormal Pap test results occurring after diagnosis of SLE, after
adjusted for smoking, nulliparity, OC use, STD history, age, race and
centre, was 1.6. The adjusted ORs for each speciﬁc immunosuppres-
sive were as follows: cyclophosphamide OR 1.3, azathioprine OR 1.2
and methotrexate OR 1.1 [31].
In conclusion, a history of STDs and use of OCs were associated
with abnormal Pap reports in this SLE sample. Immunosuppressive
exposure may confer further risk to women with SLE [31]. Since
immunosuppressive medications predispose the development of
infections (human papilloma virus/HPV, chlamydia) it is logical to
assume that this treatment contributes to the development of cervical
dysplasia and/or cervical carcinoma development.
2.5. Breast cancer in SLE
Evidence of an association between SLE and malignancy has
accumulated over the past several years [11,32–35]. An increased risk
of breast cancer has been reported in at least one SLE cohort study [34].
In a multi-center study, data were pooled from SLE cohorts at three
centers; altogether 871 female patients were included. Altogether, 15
breast cancers occurred, and the SIRwas2.1. The data suggested that the
breast cancer experience in this sample is not completely explained by
factors such as reproductive and family history, or by exogenous
hormonal exposures (hormone replacement therapy/HRT and OC use).
Other determinants, including medication exposures or genetic factors
(possibly related to estrogen receptor polymorphism or estrogen
metabolism) may also be important [36]. Interestingly, in progressive
systemic sclerosis (PSS) and SLE overlap, or in obese patients, increased
aromatization of androstenedionehas beendescribed,which eventually
leads to higher estrogen levels and elevated risk to develop breast
cancer. In SLE, the pathological immune responses can lead to
uncontrolled cell proliferation and decreased apoptosis frequency, and
ﬁnally to breast cancer development.
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in SLE
Since the pathogenic role of immunosuppressive treatment could
contribute to the development of malignancies in SLE, a case-cohort
study was performed within a multi-site international SLE cohort; the
hazard ratio (HR) was calculated for cancer after exposure to immuno-
suppressive drugs (e.g. anti-malarial drugs, systemic glucocorticoids,
non-steroidal anti-inﬂammatory drugs/NSAIDs, aspirin). Results were
assessed based on 246 cancer cases and 538 controlswithout cancer. The
adjusted HR for overall cancer risk after any immunosuppressive drug
was 0.82. Concerning hematologicalmalignancies, an increased risk after
immunosuppressive drug exposures, particularly when these were
lagged by a period of 5 years was evident (adjusted HR 2.29) [37].
4. Tumor markers in SLE
The assessment of tumor-associated antigens (TAAs) in the sera of
40 SLE patients indicated that signiﬁcantly more patients had elevated
levels of carcinoembryonic antigen (CEA), cancer antigen (CA)19-9,
CA125 and CA72-4. Themean absolute serum levels of CEA and CA15-3
were also signiﬁcantly higher in SSc compared to controls. SerumCA72-
4 correlated with central nervous system involvement, while CA125
correlated with the Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI); composite activity index. The concentration of some
TAAs may be elevated in the sera of patients with SLE in comparison to
healthy subjects. Pathogenically, most of these TAAs contain carbohy-
dratemotifs and thus theymay be involved in inﬂammation-associated
adhesive events. These carbohydrate motifs are also expressed on the
surface of leukocytes and play a role in tumor-cell attachment,
metastasis-spreading, cell adhesion and inﬂammation progression.
Furthermore, the production of some TAAs may correlate with organ
involvement or disease activity in lupus [38].
5. Conclusions
In patients with SLE, the incidence and risk of malignancy
development is increased, and mostly NHL, cervical cancer, as well
as bronchial carcinomas occur. The risk of neoplasm development in
lupus is the highest in the ﬁrst year, while in the subsequent years, the
prevalence of malignancy is further rising, as a consequence of its
general increase in the average population. Based on our survey, the
survival of patients from the time of identiﬁcation of the neoplasm is
approximately 4.5 years in general. Concerning NHL, the survival of
lupus patients is shorter, compared to the average population.
In patients with SLE, thorough follow-up, regular check-ups and
detailed neoplasm-related investigations are of utmost importance.
Further research is necessary to discover the commonpathways in lupus
andmalignancies and todevelopnovel, advanceddiagnostic procedures,
and therapeutical interventions in the combat against these neoplasms.Take-home messages
• Malignancies develop in about 4.5% of lupus patients.
• The standardized incidence ratio is the highest for non-Hodgkin's
lymphomas, Hodgkin's disease, cervical, bronchial and breast cancers.
• Shared etiopathogenic factors–common genetic predisposition, infec-
tions (EBV, STDs), hormonal status (estrogen), lifestyle-related factors
(smoking, obesity), UV-light–and the use of immune suppressive
agentsmay explain the increased risk for cancer development in lupus.
• Over-expression of B-cell activating factor (BAFF) and proliferation-
induced ligand (APRIL), aberrant apoptosis and cell-cycle regula-
tion, and chronic antigen stimulation result in over-activation,
excessive proliferation and increased longevity of B-cells both in
lupus and especially in lymphomas.• Tumor-associated antigens can be present in lupus sera and
probably are involved in inﬂammation-related adhesive processes.
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